关键信息
-
基因名
HSPA9
- 应用
-
别名
FXN;FRDA;X25;Frataxin. mitochondrial
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P38646
-
表达区间
47-679aa
-
氨基酸序列
ASEA IKGAVVGIDL GTTNSCVAVM EGKQAKVLEN AEGARTTPSV VAFTADGERL VGMPAKRQAV TNPNNTFYAT KRLIGRRYDD PEVQKDIKNV PFKIVRASNG DAWVEAHGKL YSPSQIGAFV LMKMKETAEN YLGHTAKNAV ITVPAYFNDS QRQATKDAGQ ISGLNVLRVI NEPTAAALAY GLDKSEDKVI AVYDLGGGTF DISILEIQKG VFEVKSTNGD TFLGGEDFDQ ALLRHIVKEF KRETGVDLTK DNMALQRVRE AAEKAKCELS SSVQTDINLP YLTMDSSGPK HLNMKLTRAQ FEGIVTDLIR RTIAPCQKAM QDAEVSKSDI GEVILVGGMT RMPKVQQTVQ DLFGRAPSKA VNPDEAVAIG AAIQGGVLAG DVTDVLLLDV TPLSLGIETL GGVFTKLINR NTTIPTKKSQ VFSTAADGQT QVEIKVCQGE REMAGDNKLL GQFTLIGIPP APRGVPQIEV TFDIDANGIV HVSAKDKGTG REQQIVIQSS GGLSKDDIEN MVKNAEKYAE EDRRKKERVE AVNMAEGIIH DTETKMEEFK DQLPADECNK LKEEISKMRE LLARKDSETG ENIRQAASSL QQASLKLFEM AYKKMASERE GSGSSGTGEQ KEDQKEEKQ
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HSPA9, also known as Heat Shock Protein Family A Member 9 or Mortalin, is a member of the HSP70 family of proteins that play a crucial role in cellular stress response and protein homeostasis. Research indicates that HSPA9 is involved in various cellular processes, including mitochondrial function, apoptosis, and cellular signaling pathways. Its expression is often upregulated in response to stress conditions, making it a key player in protecting cells from damage. Given its involvement in oncogenic processes and its association with several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases, HSPA9 has gained attention as a potential biomarker and therapeutic target. Studies have demonstrated that HSPA9 can influence tumor progression and resistance to therapies, highlighting the necessity for detailed investigations into its functional mechanisms. The development of recombinant HSPA9 proteins allows for in-depth studies on its structural and functional properties, facilitating the understanding of its role in various biological contexts. The exploration of HSPA9 as a therapeutic target is particularly promising due to its dual roles in promoting cell survival in stressed environments and its potential involvement in disease pathology. This research has significant implications for the development of novel therapeutic strategies aimed at modulating HSPA9 activity in disease contexts, ultimately influencing treatment approaches in oncology and other related fields. Understanding the molecular mechanisms regulated by HSPA9 can provide insights into stress-response pathways, potentially leading to advancements in targeted therapies and improved patient outcomes in conditions where cellular stress plays a critical role.
